{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:21:23Z","timestamp":1779294083230,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UOK120"],"award-info":[{"award-number":["UOK120"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UOK146"],"award-info":[{"award-number":["UOK146"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1F1A1060678"],"award-info":[{"award-number":["NRF-2020R1F1A1060678"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ajpath.2021.07.007","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T02:28:34Z","timestamp":1628044114000},"page":"1999-2008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["mTOR Inhibition Increases Transcription Factor E3 (TFE3) Activity and Modulates Programmed Death-Ligand 1 (PD-L1) Expression in Translocation Renal Cell Carcinoma"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2995-6060","authenticated-orcid":false,"given":"Hyun Jung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Hoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Sun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3076-9147","authenticated-orcid":false,"given":"So Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung Su","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-433X","authenticated-orcid":false,"given":"Ju-Young","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mee Young","family":"Sol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2021.07.007_bib1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/PAS.0b013e318031ffff","article-title":"Xp11 translocational renal cell carcinoma in adults: expanded clinical, pathological and genetic spectrum","volume":"31","author":"Argani","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib2","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1016\/j.clgc.2016.12.026","article-title":"Long-term treatment with sequential molecular targeted therapy for Xp11.2 tranloscation renal cell carcinoma: a case report and review of the literature","volume":"15","author":"Kakoki","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ajpath.2021.07.007_bib3","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2021.07.007_bib4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2021.07.007_bib5","doi-asserted-by":"crossref","first-page":"ra9","DOI":"10.1126\/scisignal.2004754","article-title":"The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris","volume":"7","author":"Martina","year":"2014","journal-title":"Sci Signal"},{"key":"10.1016\/j.ajpath.2021.07.007_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-cellbio-111315-125407","article-title":"TFEB and TFE3: linking lysosomes to cellular adaptation to stress","volume":"32","author":"Raben","year":"2016","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev.genet.38.072902.092717","article-title":"Melanocytes and the microphthalmia transcription factor network","volume":"38","author":"Steingrimsson","year":"2004","journal-title":"Annu Rev Genet"},{"key":"10.1016\/j.ajpath.2021.07.007_bib8","doi-asserted-by":"crossref","first-page":"609683","DOI":"10.3389\/fcell.2020.609683","article-title":"MiT\/TFE family of transcription factors: an evolutionary perspective","volume":"8","author":"La Spina","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrurol.2014.162","article-title":"Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers","volume":"11","author":"Kauffman","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2021.07.007_bib11","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.ajpath.2021.07.007_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2217\/thy.11.32","article-title":"mTOR inhibitors in renal cell carcinoma","volume":"8","author":"Battelli","year":"2011","journal-title":"Therapy"},{"key":"10.1016\/j.ajpath.2021.07.007_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11523-016-0463-4","article-title":"Resistance to targeted therapies in renal cancer: the importance of changing the mechanism of action","volume":"12","author":"Duran","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","article-title":"Resistance to targeted therapy in renal cell carcinoma","volume":"10","author":"Rini","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib16","doi-asserted-by":"crossref","first-page":"30756","DOI":"10.18632\/oncotarget.16481","article-title":"Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC: comparison of three different diagnostic methods","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ajpath.2021.07.007_bib17","doi-asserted-by":"crossref","first-page":"e19337","DOI":"10.1371\/journal.pone.0019337","article-title":"A rapid and simple procedure for the establishment of human normal and cancer renal primary cell cultures from surgical specimens","volume":"6","author":"Valente","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2021.07.007_bib18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/his.14047","article-title":"PD-L1 expression and infiltration by CD4+ and FoxP3+ T cells are increased in Xp11 translocation renal cell carcinoma and indicate poor prognosis","volume":"76","author":"Lee","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.ajpath.2021.07.007_bib19","doi-asserted-by":"crossref","first-page":"e0219566","DOI":"10.1371\/journal.pone.0219566","article-title":"Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma","volume":"14","author":"D'Angelo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2021.07.007_bib20","doi-asserted-by":"crossref","first-page":"e95843","DOI":"10.1371\/journal.pone.0095843","article-title":"Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma","volume":"9","author":"Martin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2021.07.007_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12964-018-0242-1","article-title":"Emerging roles and regulation of MiT\/TFE transcriptional factors","volume":"16","author":"Yang","year":"2018","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.ajpath.2021.07.007_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ajpath.2021.07.007_bib23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12929-019-0588-8","article-title":"Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway","volume":"26","author":"Wakabayashi","year":"2019","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.ajpath.2021.07.007_bib24","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558,ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib25","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2021.07.007_bib26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajpath.2021.07.007_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.critrevonc.2017.06.001","article-title":"Biomarkers of response to PD-1\/PD-L1 inhibition","volume":"116","author":"Maleki Vareki","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib28","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/ni1378","article-title":"Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity","volume":"7","author":"Huan","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib29","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.7150\/jca.35738","article-title":"Determination of the expression of PD-L1 in the morphologic spectrum of renal cell carcinoma","volume":"11","author":"Walter","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.ajpath.2021.07.007_bib30","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","article-title":"PD-L1 expression in nonclear-cell renal cell carcinoma","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib31","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","article-title":"Role of PI3K\/AKT pathway in cancer: the framework of malignant behaviour","volume":"47","author":"Jiang","year":"2020","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.ajpath.2021.07.007_bib32","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosin kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2021.07.007_bib33","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.hoc.2011.04.008","article-title":"mTOR inhibitors in advanced renal cell carcinoma","volume":"25","author":"Voss","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ajpath.2021.07.007_bib34","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.9207.1","article-title":"mTOR inhibitors in cancer therapy","volume":"5","author":"Xie","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.ajpath.2021.07.007_bib35","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.4081\/rt.2009.e53","article-title":"Temsirolimus in the treatment of renal cell carcinoma associated with Xp11.2 translocation\/TFE gene fusion proteins: a case report and review of literature","volume":"1","author":"Parikh","year":"2009","journal-title":"Rare Tumors"},{"key":"10.1016\/j.ajpath.2021.07.007_bib36","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1242\/dev.02820","article-title":"Met acts on Mdm2 via mTOR to signal cell survival during development","volume":"134","author":"Moumen","year":"2007","journal-title":"Development"},{"key":"10.1016\/j.ajpath.2021.07.007_bib37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/jclinpath-2020-206899","article-title":"Gene of the month: TFE3","volume":"73","author":"Pinto","year":"2020","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib38","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/PAS.0b013e3181e8ce5b","article-title":"Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers","volume":"34","author":"Argani","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2021.07.007_bib39","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/cncr.22677","article-title":"Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy","volume":"109","author":"Pantuck","year":"2007","journal-title":"Cancer"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944021003448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944021003448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T16:40:15Z","timestamp":1757695215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944021003448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0002944021003448"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2021.07.007","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR Inhibition Increases Transcription Factor E3 (TFE3) Activity and Modulates Programmed Death-Ligand 1 (PD-L1) Expression in Translocation Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2021.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}